Denali Therapeutics Inc. (DNLI) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YNo 10Y revenue consistency score yet — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 38 quarters in the window, leaving 21 comparable quarters; at least 28 are needed.
No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 38 quarters in the window, leaving 21 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: Latest historical P/S 864.0x · 10Y median 33.3x · 89th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | — | — | — | — | — |
| EPSEPS | — | — | — | — | — |
| Op cash flowOperating cash flow | — | — | — | — | — |
| EBITDAEBITDA | — | — | — | — | — |
| FCFFree cash flow | — | — | — | — | — |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: DNLI on the compounders surface · All compounders, ranked